Barbara Schacher Engstler
Overview
Explore the profile of Barbara Schacher Engstler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
100
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tiedt R, King F, Stamm C, Niederst M, Delach S, Zumstein-Mecker S, et al.
Cell Rep
. 2023 Mar;
42(4):112297.
PMID: 36961816
Anti-tumor efficacy of targeted therapies is variable across patients and cancer types. Even in patients with initial deep response, tumors are typically not eradicated and eventually relapse. To address these...
2.
Kim S, Tiedt R, Loo A, Horn T, Delach S, Kovats S, et al.
Oncotarget
. 2020 Apr;
11(14):1289.
PMID: 32292577
[This corrects the article DOI: 10.18632/oncotarget.26215.].
3.
Dafflon C, Gaulis S, Barys L, Kapur K, Cornacchione V, Schukur L, et al.
Oncotarget
. 2020 Mar;
11(11):956-968.
PMID: 32215184
The histone 3 lysine 79 (H3K79) methyltransferase (HMT) DOT1L is known to play a critical role for growth and survival of -rearranged leukemia. Serendipitous observations during high-throughput drug screens indicated...
4.
Baltschukat S, Engstler B, Huang A, Hao H, Tam A, Wang H, et al.
Clin Cancer Res
. 2019 Jan;
25(10):3164-3175.
PMID: 30674502
Purpose: The selective MET inhibitor capmatinib is being investigated in multiple clinical trials, both as a single agent and in combination. Here, we describe the preclinical data of capmatinib, which...
5.
Kim S, Tiedt R, Loo A, Horn T, Delach S, Kovats S, et al.
Oncotarget
. 2018 Nov;
9(81):35226-35240.
PMID: 30443290
Inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) is associated with robust antitumor activity. Ribociclib (LEE011) is an orally bioavailable CDK4/6 inhibitor that is approved for the treatment of hormone...